ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Pryce Introduces Bill To Reimbuse For Orally Administered Cancer Drugs.

May 4, 2001

Center Directors To Rewrite 5-Year Plan With Little Staff Help

March 9, 1990

CCI Gets Qualified Approval To Continue

January 18, 1980

Funding Opportunities

September 6, 2002

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

April 21, 2006

New Breast Cancer Therapies Move Into General Practice; Fisher, Miami Plan Segmental Trials

February 13, 1976